News
Support for abortion rights shows record gender gap in new US polling
A record gap has emerged between women and men in the US on abortion rights, with 61 per cent of women now identifying as pro-choice compared with just 41 per cent of men.
The divide has widened sharply in the three years since the US Supreme Court overturned Roe v Wade, the landmark ruling that had guaranteed abortion access across the country. The latest figures follow a 2024 election in which reproductive rights were a key campaign issue.
While the proportion of women identifying as pro-choice has remained stable since the Roe decision was leaked in 2022, support among men has fallen from 48 per cent in that same year to 41 per cent, according to new polling from Gallup.
Decades of Gallup data show that men and women have rarely differed by more than 10 points on the issue—until now.
The two groups are also further apart than ever in how they view the morality of abortion.
Fifty-seven per cent of women say it is morally acceptable, compared with just 40 per cent of men. Similarly, 56 per cent of women believe abortion should be legal in all or most cases, compared with 41 per cent of men.
Gallup’s director of US social research, Lydia Saad, said the widening gap is more a result of changing attitudes among women than any significant shift among men.
In 2021, before Roe was overturned, 52 per cent of women and 45 per cent of men identified as pro-choice.
Saad said: “In general, we see that with abortion, the party that wants to change the status quo is the one that has more energy on the issue.
“For years, it was more the pro-life respondents who said that they will only support a candidate who shares their views on that issue. Whereas, since 2022, we’ve seen it flip.”
She added that while political shocks can lead to short-term shifts in opinion, these often fade over time.
Men’s declining support may reflect a reversion to previous norms—but she noted it was striking that women’s views remained strongly affected.
She said: “A line had been crossed for women.
“If you were generally supportive of abortion rights before, you became much more so.”
Democratic men, like women overall, have also grown more likely to back abortion rights.
Between 2020 and 2021, 63 per cent of Democratic men supported legal abortion in most cases; by 2025, that figure had risen to 78 per cent.
Saad said it remains unclear why overall support among men has declined.
Despite being the lowest level of support for the pro-choice label among men in a decade, she is not convinced the trend will continue.
She said: “It’s more just an out of sight, out of mind issue for men.
“Whereas for women—it’s just been more salient.”
She added that men may not necessarily be becoming more anti-abortion, but rather more conservative overall.
Men are already more likely to identify as Republicans, a group that typically opposes abortion rights. Only 19 per cent of Republican men now support legal abortion in most circumstances.
Gallup’s data may also reflect shifts among younger men, with more conservative voting seen in the 2024 election.
Fifty-six per cent of men aged 18 to 29 voted for Donald Trump.
Saad said: “We have to see where this goes.
“If it’s sustained, then we would really have to take a close look at why.”
Small bowel microbiome differences between women and men may help explain why some conditions are more common in women, a study suggests.
The small bowel microbiome is the community of microorganisms living in this part of the digestive tract, where they play vital roles in immune function, metabolism and hormonal regulation.
Researchers found differences between women and men in the composition and organisation of these microbial communities. One bacterial community containing Granulicatella was found only in women.
The study was conducted by investigators at Cedars-Sinai Health Sciences University.
Ruchi Mathur, director of clinical research and clinical operations for the Medically Associated Science and Technology (MAST) Program at Cedars-Sinai and corresponding author of the study, said: “One intriguing finding was a bacterial community containing Granulicatella, which we found only in women.
“Bacteria in this community appear at increased levels in women with polyendocrine metabolic ovarian syndrome, formerly known as polycystic ovary syndrome.”
The researchers also identified differences between women and men in how microbes in the small bowel produce fructans, complex carbohydrates known to trigger digestive symptoms in irritable bowel syndrome (IBS).
IBS is far more common in women than men.
Mathur, who is also a professor of medicine, said: “Our findings show that biological sex is a critical variable in the small bowel microbiome.
“We must consider it as we move toward more personalised approaches to understanding and treating disease.”
An experimental cancer drug reduced bone loss and body fat in mice modelling post-menopausal changes, early research suggests.
The compound, CADD522, appeared to strengthen bones and help the animals stay leaner after surgery designed to mimic hormonal changes seen after menopause.
The treatment remains at an early experimental stage and has so far only been tested in animals.
The study, led by the University of East Anglia, investigated CADD522, which was originally developed to block a protein involved in the growth and spread of several cancers.
Mice treated with the compound for eight weeks showed significant improvements in bone health. Scans found increased bone volume and better preservation of the honeycomb-like structures inside bones that are crucial for strength and resilience.
Blood tests suggested the treatment stimulated new bone growth without interfering with the body’s normal process of breaking down and rebuilding bone.
Dr Darrell Green, lead researcher from UEA’s Norwich Medical School, said: “Osteoporosis affects around one in three women over the age of 50, leaving sufferers vulnerable to painful fractures that can seriously impact quality of life.
“Current treatments exist, but many are plagued by side effects, safety concerns or inconvenient dosing schedules that make long-term use difficult.”
The researchers also found that mice receiving CADD522 weighed less than untreated mice despite eating the same amount of food.
They had less body fat and fewer fat deposits in their bone marrow, a process commonly seen after menopause and linked to declining bone health.
The team also examined brain tissue and found that the drug appeared to reverse several menopause-related changes in fatty acids.
Levels of omega-3 fats including DHA remained largely intact, while several other lipid abnormalities shifted back towards healthier patterns.
Green said: “We didn’t directly test for memory or thinking ability, but our work raises questions about whether this drug could one day help address wider menopause-related health problems.”
Safety experiments in mice, rats and dogs found that CADD522 could be taken orally and was well tolerated.
The compound also appeared to be metabolised more slowly in human tissue than in rodents, potentially improving its performance in people.
“This is still in the early stages and has so far only been tested in animals but we hope that the benefits will translate to humans to ultimately reduce fracture rates,” added Green.
The research was led by UEA in collaboration with the University of Maryland, the Scintillon Research Institute in San Diego and the University of Stirling.
Safety testing was funded by The Sir William Coxen Trust as part of the development of CADD522 as a childhood cancer treatment.
Weight loss surgery was linked to more regular periods and fewer polyendocrine metabolic ovarian syndrome (PMOS) symptoms in women aged 18 to 45 living with obesity in a recent study.
The researchers recommend that women undergoing the procedure have access to preconception care and reproductive counselling to support their reproductive health.
Researchers at the University of Surrey analysed data over 24 months from 84 women who underwent bariatric surgery and 18 women living with obesity who did not have surgery.
Of those who underwent surgery, 49 had gastric bypass procedures and 35 had gastric sleeve surgery.
Women who underwent metabolic bariatric surgery lost more than 30kg on average at 12 and 24 months after the procedure.
Among women with polycystic ovaries, the condition persisted in only 10 per cent after 24 months.
Women also reported a resolution of clinical hirsutism, or excess body hair, by 12 months.
Women who had previously experienced irregular periods reported more regular menstrual cycles after surgery.
Professor Martin Whyte, co-author of the study and professor of metabolic medicine at the University of Surrey, said: “A large proportion of those undergoing bariatric surgery are women of reproductive age, who may be planning a pregnancy in the coming years.
“So much remains unknown about the impact of this type of surgery on women who are planning to have children.
“This raises the question of when the ideal time after surgery is to conceive.”
Women have a higher prevalence of obesity than men, with 57 per cent of women in the UK classified as overweight and 27 per cent living with obesity, which can affect fertility and the health of an unborn baby.
The researchers said 17 women had healthy pregnancies following surgery.
Although this was not specifically examined in the study, no difference in birth weight was observed between babies conceived within or after the first year.
Dr Kathryn Hart, co-author of the study and associate professor in nutrition and dietetics at the University of Surrey, said: “What we have found is that bariatric surgery positively affects the reproductive health of women living with obesity and can improve the likelihood of them having a healthy pregnancy after surgery.
“Dysregulated hormone levels, irregular periods and conditions such as polycystic ovaries are affected by obesity.
“By reducing this, what we have seen is that it can lead to improvements without the need for medication.
“We would suggest that clinicians consider medical intervention for obesity to treat irregularities in the menstrual cycle and issues with fertility.”
Diagnosis2 weeks agoMajor UK study could be a ‘game-changer’ for heavy periods and endometriosis
Entrepreneur7 days agoKOVE Medical raises €1.7 million to improve safety of foetal surgery
Fertility2 weeks agoOne week left to apply: W Accelerate with Merck KGaA and M Ventures
Mental health1 week agoUK study aims to transform maternity care for high-risk pregnancies
Menopause2 weeks agoQuarter of women miss work due to menstual symptoms, survey finds
Mental health2 weeks agoPMDD after SSRIs or hormones: Why the brain may be the missing treatment target
Diagnosis2 weeks agoArk Surgical secures further institutional backing to accelerate US expansion
Menopause5 days agoMenopause hormone treatment may ease brain fog, study suggests